Lixte Selling General Administrative vs Total Assets Analysis

LIXTW Stock  USD 0.03  0.0001  0.36%   
Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Selling General Administrative and its Total Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Selling General Administrative vs Total Assets

Selling General Administrative vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Selling General Administrative account and Total Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between Lixte Biotechnology's Selling General Administrative and Total Assets is 0.79. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Total Assets in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Selling General Administrative and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Lixte Biotechnology Holdings are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Selling General Administrative i.e., Lixte Biotechnology's Selling General Administrative and Total Assets go up and down completely randomly.

Correlation Coefficient

0.79
Relationship DirectionPositive 
Relationship StrengthSignificant

Selling General Administrative

Total Assets

Total assets refers to the total amount of Lixte Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lixte Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, Lixte Biotechnology's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 3.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.02 in 2024.
 2023 2024 (projected)
Interest Income20.5K12.4K
Gross Profit180K160K

Lixte Biotechnology fundamental ratios Correlations

0.650.240.96-0.97-0.760.950.960.73-0.280.760.241.0-0.3-0.320.460.81-0.34-0.32-0.110.91-0.11-0.660.40.350.92
0.650.460.63-0.63-0.720.630.640.540.030.70.460.65-0.19-0.30.410.68-0.5-0.3-0.230.750.18-0.470.420.720.7
0.240.460.21-0.22-0.450.220.230.260.180.431.00.240.13-0.790.660.33-0.21-0.79-0.120.250.33-0.010.710.480.22
0.960.630.21-1.0-0.841.01.00.83-0.310.860.210.96-0.4-0.30.420.8-0.38-0.3-0.350.88-0.14-0.710.320.340.92
-0.97-0.63-0.22-1.00.83-1.0-1.0-0.810.31-0.85-0.22-0.970.380.3-0.43-0.790.420.30.32-0.890.170.72-0.33-0.34-0.92
-0.76-0.72-0.45-0.840.83-0.84-0.84-0.860.35-0.99-0.45-0.750.380.48-0.51-0.730.280.480.59-0.720.080.71-0.55-0.69-0.87
0.950.630.221.0-1.0-0.841.00.82-0.310.860.220.95-0.39-0.30.430.79-0.43-0.3-0.360.88-0.17-0.720.320.330.92
0.960.640.231.0-1.0-0.841.00.83-0.280.860.230.96-0.4-0.310.440.79-0.42-0.31-0.360.88-0.13-0.710.330.330.92
0.730.540.260.83-0.81-0.860.820.83-0.20.890.260.73-0.77-0.20.310.86-0.34-0.2-0.60.77-0.08-0.560.290.480.86
-0.280.030.18-0.310.310.35-0.31-0.28-0.2-0.330.18-0.28-0.010.010.04-0.18-0.20.010.1-0.10.780.37-0.03-0.31-0.26
0.760.70.430.86-0.85-0.990.860.860.89-0.330.430.76-0.44-0.460.460.75-0.31-0.46-0.640.74-0.08-0.680.510.650.87
0.240.461.00.21-0.22-0.450.220.230.260.180.430.240.13-0.790.660.33-0.21-0.79-0.120.250.33-0.010.710.480.22
1.00.650.240.96-0.97-0.750.950.960.73-0.280.760.24-0.29-0.320.460.81-0.34-0.32-0.10.91-0.11-0.660.390.340.91
-0.3-0.190.13-0.40.380.38-0.39-0.4-0.77-0.01-0.440.13-0.29-0.350.16-0.620.32-0.350.51-0.450.120.180.19-0.21-0.49
-0.32-0.3-0.79-0.30.30.48-0.3-0.31-0.20.01-0.46-0.79-0.32-0.35-0.55-0.17-0.11.00.12-0.22-0.270.11-0.87-0.29-0.25
0.460.410.660.42-0.43-0.510.430.440.310.040.460.660.460.16-0.550.4-0.13-0.550.00.290.31-0.540.440.290.39
0.810.680.330.8-0.79-0.730.790.790.86-0.180.750.330.81-0.62-0.170.4-0.38-0.17-0.180.83-0.06-0.510.230.510.82
-0.34-0.5-0.21-0.380.420.28-0.43-0.42-0.34-0.2-0.31-0.21-0.340.32-0.1-0.13-0.38-0.10.27-0.490.170.270.03-0.09-0.38
-0.32-0.3-0.79-0.30.30.48-0.3-0.31-0.20.01-0.46-0.79-0.32-0.351.0-0.55-0.17-0.10.12-0.22-0.270.11-0.87-0.29-0.25
-0.11-0.23-0.12-0.350.320.59-0.36-0.36-0.60.1-0.64-0.12-0.10.510.120.0-0.180.270.12-0.180.080.3-0.14-0.3-0.35
0.910.750.250.88-0.89-0.720.880.880.77-0.10.740.250.91-0.45-0.220.290.83-0.49-0.22-0.18-0.08-0.530.330.470.9
-0.110.180.33-0.140.170.08-0.17-0.13-0.080.78-0.080.33-0.110.12-0.270.31-0.060.17-0.270.08-0.080.170.22-0.06-0.08
-0.66-0.47-0.01-0.710.720.71-0.72-0.71-0.560.37-0.68-0.01-0.660.180.11-0.54-0.510.270.110.3-0.530.17-0.16-0.3-0.72
0.40.420.710.32-0.33-0.550.320.330.29-0.030.510.710.390.19-0.870.440.230.03-0.87-0.140.330.22-0.160.460.43
0.350.720.480.34-0.34-0.690.330.330.48-0.310.650.480.34-0.21-0.290.290.51-0.09-0.29-0.30.47-0.06-0.30.460.51
0.920.70.220.92-0.92-0.870.920.920.86-0.260.870.220.91-0.49-0.250.390.82-0.38-0.25-0.350.9-0.08-0.720.430.51
Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.7M5.2M5.1M5.6M4.3M2.2M
Other Current Liab237.9K10.5K302.9K394.8K313.9K171.6K
Total Current Liabilities237.9K216.5K302.9K394.8K313.9K290.7K
Total Stockholder Equity2.4M5.0M4.8M5.2M4.0M4.2M
Net Debt(2.6M)(5.1M)(4.8M)(5.4M)(4.2M)(4.0M)
Retained Earnings(27.1M)(30.4M)(37.1M)(43.4M)(48.5M)(46.1M)
Cash2.6M5.1M4.8M5.4M4.2M4.4M
Cash And Short Term Investments2.6M5.1M4.8M5.4M4.2M4.4M
Common Stock Shares Outstanding1.1M1.1M1.3M158.2K1.9M1.8M
Liabilities And Stockholders Equity2.7M5.2M5.1M5.6M4.3M2.2M
Other Stockholder Equity26.0M31.9M38.4M45.1M49.0M51.4M
Total Liab237.9K216.5K302.9K394.8K313.9K290.7K
Total Current Assets2.7M5.2M5.1M5.6M4.2M2.2M
Accounts Payable143.5K190.3K226.0K229.8K156.8K169.4K
Other Current Assets58.8K159.2K10.2K10.4K27.1K25.8K
Short Term Debt210.9K237.9K302.9K394.8K313.9K193.4K
Current Deferred Revenue94.3K15.8K77.0K165.0K157.1K81.5K
Capital Surpluse20.0M25.3M26.0M31.9M36.6M26.5M
Net Invested Capital(1.1M)1.5M1.3M1.7M494.8K317K
Net Working Capital2.4M5.0M4.8M5.2M4.0M4.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.